{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T03:49:45Z","timestamp":1784173785574,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100032683","name":"Akita University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100032683","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The phase III ASC4FIRST study (NCT04971226) demonstrated superior efficacy and favorable safety and tolerability for asciminib against investigator-selected tyrosine kinase inhibitors (IS-TKI) in newly diagnosed chronic myeloid leukemia (CML). Results of a subgroup analysis in Japanese patients are presented here.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult patients were randomized 1:1 to asciminib or IS-TKI following stratification by European Treatment and Outcome Study long-term survival risk score and prerandomization-selected TKI (imatinib and second-generation [2G] TKI strata). At week 48, major molecular response (MMR) rate in all patients and imatinib stratum (primary endpoints) were assessed along with MR4.0, MR4.5, and safety (cutoff: November 28, 2023).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In Japanese patients (asciminib, n\u2009=\u200921; IS-TKI, n\u2009=\u200917 [imatinib\/2G TKI, n\u2009=\u20098\/9]), the MMR rate was higher with asciminib (81.0%) than IS-TKI (47.1%), and versus imatinib (asciminib: 100%; imatinib: 25.0% [imatinib stratum]). More patients on asciminib than IS-TKI achieved MR4.0 (57.1% vs. 11.8%) and MR4.5 (28.6% vs. 5.9%). Fewer grade\u2009\u2265\u20093 adverse events (AEs; 42.9%, 50.0%, and 55.6%) and AEs leading to treatment discontinuation (0%, 37.5%, and 11.1%) occurred with asciminib than imatinib or 2G TKI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Outcomes in Japanese patients were consistent with the ASC4FIRST overall population. Asciminib may be a therapy of choice for Japanese patients with CML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12185-025-04014-z","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T09:27:45Z","timestamp":1748251665000},"page":"647-659","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Asciminib in patients with newly diagnosed chronic myeloid leukemia: results from the Japanese subgroup of ASC4FIRST"],"prefix":"10.1007","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-3787","authenticated-orcid":false,"given":"Naoto","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikane","family":"Kikushige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohisa","family":"Nakamae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Ichii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Kirito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ikezoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Hiramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Osako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Malek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"issue":"7","key":"4014_CR1","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","volume":"36","author":"TH Br\u00fcmmendorf","year":"2022","unstructured":"Br\u00fcmmendorf TH, Cortes JE, Milojkovic D, Gambacorti-Passerini C, Clark RE, le Coutre P, et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022;36(7):1825\u201333.","journal-title":"Leukemia"},{"issue":"20","key":"4014_CR2","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333\u201340.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4014_CR3","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044\u201354.","journal-title":"Leukemia"},{"issue":"11","key":"4014_CR4","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O'Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994\u20131004.","journal-title":"N Engl J Med"},{"issue":"11","key":"4014_CR5","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.3390\/jcm9113671","volume":"9","author":"R Hehlmann","year":"2020","unstructured":"Hehlmann R. The new ELN recommendations for treating CML. J Clin Med. 2020;9(11):3671.","journal-title":"J Clin Med"},{"issue":"1","key":"4014_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12185-024-03865-2","volume":"121","author":"N Takahashi","year":"2024","unstructured":"Takahashi N, Takenaka K, Iriyama N, Kirito K, Kawaguchi T, Kimura S, et al. JSH practical guidelines for hematological malignancies, 2023: leukemia-4. Chronic myeloid leukemia (CML)\/myeloproliferative neoplasms (MPN). Int J Hematol. 2024;121(1):5\u201338.","journal-title":"Int J Hematol"},{"issue":"4","key":"4014_CR7","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966\u201384.","journal-title":"Leukemia"},{"key":"4014_CR8","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myeloid Leukemia V.3.2025. \u00a9 National Comprehensive Cancer Network, Inc. 2024. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org. Accessed 4 Dec 2024."},{"issue":"5","key":"4014_CR9","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","volume":"2","author":"K Sasaki","year":"2015","unstructured":"Sasaki K, Strom SS, O\u2019Brien S, Jabbour E, Ravandi F, Konopleva M, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2(5):e186\u201393.","journal-title":"Lancet Haematol"},{"issue":"1","key":"4014_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-021-01055-9","volume":"14","author":"J Cortes","year":"2021","unstructured":"Cortes J, Lang F. Third-line therapy for chronic myeloid leukemia: current status and future directions. J Hematol Oncol. 2021;14(1):44.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4014_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/ejh.13524","volume":"106","author":"C Gambacorti-Passerini","year":"2021","unstructured":"Gambacorti-Passerini C, Chen C, Davis C, Sen GP, Guyan C, Hehlmann R, et al. Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic-phase CML in clinical practice: 3-year European SIMPLICITY data. Eur J Haematol. 2021;106(1):82\u20139.","journal-title":"Eur J Haematol"},{"issue":"1","key":"4014_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/ajh.25306","volume":"94","author":"R Hehlmann","year":"2019","unstructured":"Hehlmann R, Cortes JE, Zyczynski T, Gambacorti-Passerini C, Goldberg SL, Mauro MJ, et al. Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2019;94(1):46\u201354.","journal-title":"Am J Hematol"},{"issue":"5","key":"4014_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11899-023-00703-w","volume":"18","author":"N Held","year":"2023","unstructured":"Held N, Atallah EL. Real-world management of CML: outcomes and treatment patterns. Curr Hematol Malig Rep. 2023;18(5):167\u201375.","journal-title":"Curr Hematol Malig Rep"},{"key":"4014_CR14","doi-asserted-by":"publisher","first-page":"5190","DOI":"10.1182\/blood-2023-180789","volume":"142","author":"VK Kota","year":"2023","unstructured":"Kota VK, Wei D, Yang D, Romdhani H, Latremouille-Viau D, Gu\u00e9rin A, et al. treatment patterns and modifi cations of tyrosine kinase inhibitors (TKI) therapy in earlylines in patients with chronic myeloid leukemia in chronic phase (CML-CP): real-world analysis from a large commercial claims database in the United States (US). Blood. 2023;142:5190.","journal-title":"Blood"},{"issue":"1","key":"4014_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/ejh.13081","volume":"101","author":"S Ota","year":"2018","unstructured":"Ota S, Matsukawa T, Yamamoto S, Ito S, Shindo M, Sato K, et al. Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Eur J Haematol. 2018;101(1):95\u2013105.","journal-title":"Eur J Haematol"},{"issue":"4","key":"4014_CR16","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s12185-019-02613-1","volume":"109","author":"M Kizaki","year":"2019","unstructured":"Kizaki M, Takahashi N, Iriyama N, Okamoto S, Ono T, Usui N, et al. Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the new TARGET system. Int J Hematol. 2019;109(4):426\u201339.","journal-title":"Int J Hematol"},{"issue":"6","key":"4014_CR17","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s12185-017-2208-2","volume":"105","author":"H Nakamae","year":"2017","unstructured":"Nakamae H, Fujisawa S, Ogura M, Uchida T, Onishi Y, Taniwaki M, et al. Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report. Int J Hematol. 2017;105(6):792\u2013804.","journal-title":"Int J Hematol"},{"issue":"1","key":"4014_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12185-021-03216-5","volume":"115","author":"H Nakamae","year":"2022","unstructured":"Nakamae H, Yamamoto M, Sakaida E, Kanda Y, Ohmine K, Ono T, et al. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow-up of the Japanese subgroup of the randomized ENESTnd trial. Int J Hematol. 2022;115(1):33\u201342.","journal-title":"Int J Hematol"},{"issue":"6","key":"4014_CR19","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s12185-022-03435-4","volume":"116","author":"T Ono","year":"2022","unstructured":"Ono T, Hino M, Matsumura I, Fujisawa S, Ishizawa K, Sakaida E, et al. Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study. Int J Hematol. 2022;116(6):871\u201382.","journal-title":"Int J Hematol"},{"key":"4014_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106458","volume":"98","author":"PW Manley","year":"2020","unstructured":"Manley PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020;98: 106458.","journal-title":"Leuk Res"},{"issue":"21","key":"4014_CR21","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","volume":"138","author":"D R\u00e9a","year":"2021","unstructured":"R\u00e9a D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138(21):2031\u201341.","journal-title":"Blood"},{"issue":"3","key":"4014_CR22","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","volume":"37","author":"A Hochhaus","year":"2023","unstructured":"Hochhaus A, R\u00e9a D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023;37(3):617\u201326.","journal-title":"Leukemia"},{"issue":"3","key":"4014_CR23","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s12185-024-03805-0","volume":"120","author":"Y Minami","year":"2024","unstructured":"Minami Y, Doki N, Matsuoka H, Yokota T, Tomita A, Takahashi N, et al. Asciminib in patients with CML-CP previously treated with \u2265 2 tyrosine kinase inhibitors: 96-week results from the Japanese subgroup analysis of the ASCEMBL study. Int J Hematol. 2024;120(3):305\u201313.","journal-title":"Int J Hematol"},{"issue":"3","key":"4014_CR24","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1002\/cam4.5212","volume":"12","author":"J Yuda","year":"2023","unstructured":"Yuda J, Doki N, Matsuoka H, Yokota T, Tomita A, Takahashi N, et al. Asciminib vs bosutinib in CML patients pretreated with \u22652 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study. Cancer Med. 2023;12(3):2990\u20138.","journal-title":"Cancer Med"},{"issue":"24","key":"4014_CR25","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381(24):2315\u201326.","journal-title":"N Engl J Med"},{"key":"4014_CR26","unstructured":"Novartis Europharm Limited. Scemblix 40 mg film-coated tablets\u2014summary of product characteristics (SmPC). 2022. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2022\/20220825156432\/anx_156432_en.pdf. Accessed 31 July 2024."},{"key":"4014_CR27","unstructured":"Novartis Pharmaceuticals Corp. East Hanover: Scemblix [prescribing information]. 2021. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/scemblix.pdf. Accessed 31 July 2024."},{"key":"4014_CR28","unstructured":"Pharmaceuticals and Medical Devices Agency. Antineoplastic agents\/tyrosine kinase inhibitors (ABL Myristoyl pocket binding inhibitor) asciminib hydrochloride tablets. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/300242_4291077F1027_1_03. Accessed 31 July 2024."},{"issue":"10","key":"4014_CR29","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2400858","volume":"391","author":"A Hochhaus","year":"2024","unstructured":"Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, et al. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2024;391(10):885\u201398.","journal-title":"N Engl J Med"},{"key":"4014_CR30","unstructured":"Food and Drug Administration. Highlights of prescribing information. Scemblix tablets for oral use. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/215358Orig1s008lbl.pdf. Accessed 2 Jan 2025."},{"issue":"5","key":"4014_CR31","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s12185-011-0841-8","volume":"93","author":"H Nakamae","year":"2011","unstructured":"Nakamae H, Shibayama H, Kurokawa M, Fukuda T, Nakaseko C, Kanda Y, et al. Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd. Int J Hematol. 2011;93(5):624\u201332.","journal-title":"Int J Hematol"},{"issue":"1","key":"4014_CR32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s12185-021-03144-4","volume":"114","author":"C Chuah","year":"2021","unstructured":"Chuah C, Koh LP, Numbenjapon T, Zang DY, Ong KH, Do YR, et al. Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. Int J Hematol. 2021;114(1):65\u201378.","journal-title":"Int J Hematol"},{"issue":"11","key":"4014_CR33","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/leu.2017.253","volume":"31","author":"R Hehlmann","year":"2017","unstructured":"Hehlmann R, Lauseker M, Sau\u00dfele S, Pfirrmann M, Krause S, Kolb HJ, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31(11):2398\u2013406.","journal-title":"Leukemia"},{"issue":"9","key":"4014_CR34","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","volume":"123","author":"TP Hughes","year":"2014","unstructured":"Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014;123(9):1353\u201360.","journal-title":"Blood"},{"issue":"5","key":"4014_CR35","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s11899-021-00653-1","volume":"16","author":"E Atallah","year":"2021","unstructured":"Atallah E, Sweet K. Treatment-free remission: the new goal in CML therapy. Curr Hematol Malig Rep. 2021;16(5):433\u20139.","journal-title":"Curr Hematol Malig Rep"},{"issue":"9","key":"4014_CR36","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s40262-024-01411-1","volume":"63","author":"FP Combes","year":"2024","unstructured":"Combes FP, Sy SKB, Li YF, Lorenzo S, Dasgupta K, Kapoor S, et al. Dose justification for asciminib in patients with Philadelphia chromosome-positive chronic myeloid leukemia with and without the T315I mutation. Clin Pharmacokinet. 2024;63(9):1301\u201312.","journal-title":"Clin Pharmacokinet"},{"key":"4014_CR37","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Le Coutre P, Milojkovic D, Kim DDH, Lim SM, Pavlovsky C, et al. Asciminib shows high efficacy and favorable tolerability at 80 mg once daily and 40 mg twice daily in patients with chronic phase chronic myelogenous leukemia previously treated with 2 or more tyrosine kinase inhibitors: primary analysis from the ASC4OPT Study. Blood. 2024(Supplement 1):4526.","DOI":"10.1182\/blood-2024-200017"},{"issue":"17","key":"4014_CR38","doi-asserted-by":"publisher","first-page":"4354","DOI":"10.3390\/cancers15174354","volume":"15","author":"O Kronick","year":"2023","unstructured":"Kronick O, Chen X, Mehra N, Varmeziar A, Fisher R, Kartchner D, et al. Hematological adverse events with tyrosine kinase inhibitors for chronic myeloid leukemia: a systematic review with meta-analysis. Cancers (Basel). 2023;15(17):4354.","journal-title":"Cancers (Basel)."}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04014-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04014-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04014-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T20:37:18Z","timestamp":1761770238000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04014-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["4014"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04014-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Naoto Takahashi:\n                      Grants\/Contracts\n                      : Novartis Pharma, Asahi-Kasei Pharma Corporation and Otsuka Pharmaceutical (finance to the institution for scientific research);\n                      Honoraria\n                      : Pfizer, Novartis Pharma, and Otsuka Pharmaceutical (seminar presentations). Yoshikane Kikushige:\n                      Honoraria\n                      : Novartis Pharma (seminar presentation). Hirohisa Nakamae:\n                      Grants\/Contracts\n                      : Novartis Pharma and Bristol Myers Squibb (grants);\n                      Consulting fees:\n                      Novartis Pharma (advisory consultation);\n                      Honoraria\n                      : Otsuka Pharmaceutical, Novartis Pharma, and Bristol Myers Squibb (lectures). Tatsunori Goto: no disclosures. Akihiro Tomita:\n                      Grants\/Contracts\n                      : Chugai Pharmaceutical, Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Sumitomo Pharmaceutical, Nippon Kayaku Co., Ltd., Otsuka Pharmaceutical, Takeda Pharmaceutical, Mochida Pharmaceutical, Asahi Kasei Pharma Co., Taiho Pharmaceutical, and Shionogi & Co., Ltd. (grants);\n                      Honoraria:\n                      \u00a0Chugai Pharmaceutical, Ono Pharmaceutical, AstraZeneca K.K, AbbVie GK, and Nippon Shinyaku Co., Ltd.\u00a0(lectures). Michiko Ichii:\n                      Honoraria\n                      : Novartis Pharmaceuticals and Bristol Myers Squibb (lectures). Satoshi Ito:\n                      Honoraria\n                      : Johnson & Johnson. Takanori Teshima:\n                      Manuscript development:\n                      Novartis Pharma K.K. (funding, medical writing, article processing charges);\n                      Grants:\n                      Chugai Pharmaceutical Co., Ltd., Fuji Pharma Co., Ltd., Nippon Shinyaku Co., Ltd., Nippon Kayaku Co., Ltd., Kyowa Kirin Co., Ltd., Eisai Co., Ltd., Sumitomo Pharma Co., Ltd., Asahi Kasei Pharma Corporation., Shionogi & Co., Ltd., and JCR Pharmaceuticals Co., Ltd. (research grants);\n                      Contracts\n                      : Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd., LUCA Science Inc., Priothera SAS, and PharmaEssentia Corporation (clinical trial contacts);\n                      Consulting fees:\n                      Nippon Shinyaku Co., Ltd., Kyowa Kirin Co., Ltd., Meiji Seika Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and Gilead Sciences Inc;\n                      Honoraria:\n                      Astellas Pharma Inc., AbbVie GK, AstraZeneca plc, Asahi Kasei Pharma Corporation, Gilead Sciences Inc., Nippon Shinyaku Co., Ltd., Kyowa Kirin Co., Ltd., Meiji Seika Pharma Co., Ltd., Novartis Pharma K.K., Bristol Myers Squibb K.K., Pfizer Inc., Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co., Ltd., and Nippon Kayaku Co., Ltd. (lectures);\n                      Leadership\/Fiduciary role:\n                      Japanese Society of Hematology (Director), Japanese Society for Transplantation and Cellular Therapy (President), and Japan Society of Transfusion Medicine and Cell Therapy (Director). Keita Kirito:\n                      Honoraria:\n                      PharmaEssentia JAPAN, GlaxoSmithKline, and Takeda Pharmaceuticals (lectures). Takayuki Ikezoe:\n                      Honoraria:\n                      Novartis, Otsuka, Pfizer, and Amgen (educational events). Kaoru Hatano: no disclosures. Hirokazu Tanaka: no disclosures. Nobuhiro Hiramoto: no disclosures. Ryohei Osako: Employee of Novartis Pharma K.K. Makoto Aoki: Employee of Novartis Pharma K.K. Kamel Malek: Employee of Novartis AG and shareholder in Novartis. Yasunori Ueda: no disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}